These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 19491824)
21. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Velayos FS; Terdiman JP; Walsh JM Am J Gastroenterol; 2005 Jun; 100(6):1345-53. PubMed ID: 15929768 [TBL] [Abstract][Full Text] [Related]
22. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. Qiu X; Ma J; Wang K; Zhang H Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680 [TBL] [Abstract][Full Text] [Related]
23. Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine. Prenzler A; Yen L; Mittendorf T; von der Schulenburg JM BMC Health Serv Res; 2011 Jul; 11():157. PubMed ID: 21729262 [TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of Screening Colonoscopy in Iranian High Risk Population. Javadinasab H; Daroudi R; Salimzadeh H; Delavari A; Vezvaie P; Malekzadeh R Arch Iran Med; 2017 Sep; 20(9):564-571. PubMed ID: 29048918 [TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness and projected national impact of colorectal cancer screening in France. Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557 [TBL] [Abstract][Full Text] [Related]
26. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia. Ladabaum U; Mannalithara A Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556 [TBL] [Abstract][Full Text] [Related]
27. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis. Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770 [TBL] [Abstract][Full Text] [Related]
28. Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. Tindall WN; Boltri JM; Wilhelm SM J Manag Care Pharm; 2007 Sep; 13(7 Suppl A):S2-12; quiz S13-4. PubMed ID: 17874873 [TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Sonnenberg A; Delcò F; Inadomi JM Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584 [TBL] [Abstract][Full Text] [Related]
30. [Colorectal cancer in inflammatory bowel disease]. Henriksen M; Moum B Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2696-9. PubMed ID: 17952155 [TBL] [Abstract][Full Text] [Related]
31. Probiotics for maintenance of remission in ulcerative colitis. Iheozor-Ejiofor Z; Kaur L; Gordon M; Baines PA; Sinopoulou V; Akobeng AK Cochrane Database Syst Rev; 2020 Mar; 3(3):CD007443. PubMed ID: 32128794 [TBL] [Abstract][Full Text] [Related]
32. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Ungaro RC; Limketkai BN; Jensen CB; Allin KH; Agrawal M; Ullman T; Colombel JF; Jess T Gut; 2019 Jun; 68(6):977-984. PubMed ID: 30420398 [TBL] [Abstract][Full Text] [Related]
33. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. Mitra D; Hodgkins P; Yen L; Davis KL; Cohen RD BMC Gastroenterol; 2012 Sep; 12():132. PubMed ID: 23006789 [TBL] [Abstract][Full Text] [Related]
34. Probiotics for induction of remission in ulcerative colitis. Kaur L; Gordon M; Baines PA; Iheozor-Ejiofor Z; Sinopoulou V; Akobeng AK Cochrane Database Syst Rev; 2020 Mar; 3(3):CD005573. PubMed ID: 32128795 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. Ford AC; Khan KJ; Achkar JP; Moayyedi P Am J Gastroenterol; 2012 Feb; 107(2):167-76; author reply 177. PubMed ID: 22108446 [TBL] [Abstract][Full Text] [Related]
36. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ladabaum U; Chopra CL; Huang G; Scheiman JM; Chernew ME; Fendrick AM Ann Intern Med; 2001 Nov; 135(9):769-81. PubMed ID: 11694102 [TBL] [Abstract][Full Text] [Related]
37. Surveillance colonoscopy is cost-effective for patients with adenomas who are at high risk of colorectal cancer. Saini SD; Schoenfeld P; Vijan S Gastroenterology; 2010 Jun; 138(7):2292-9, 2299.e1. PubMed ID: 20226186 [TBL] [Abstract][Full Text] [Related]
38. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare. Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156 [TBL] [Abstract][Full Text] [Related]
39. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Marshall JK; Thabane M; Steinhart AH; Newman JR; Anand A; Irvine EJ Cochrane Database Syst Rev; 2012 Nov; 11():CD004118. PubMed ID: 23152224 [TBL] [Abstract][Full Text] [Related]